BUCHANG PHARMA(SH:603858) Xin Lang Cai Jing·2025-10-30 05:15Core Points - On October 30, 2023, Bichang Pharmaceutical experienced a decline of 5.03%, with a stock price of 17.19 CNY per share, a trading volume of 251 million CNY, a turnover rate of 1.36%, and a total market capitalization of 18.128 billion CNY [1] Company Overview - Shandong Bichang Pharmaceutical Co., Ltd. is located at 369 Zhonghua West Road, Mudan District, Heze City, Shandong Province, and was established on May 10, 2001, with its listing date on November 18, 2016 [1] - The company's main business involves the research, production, and sales of traditional Chinese medicine, with revenue composition as follows: 82.34% from traditional Chinese medicine, 10.08% from chemical drugs, 6.61% from medical devices, and 0.97% from other sources [1] Shareholder Activity - Among the top ten circulating shareholders of Bichang Pharmaceutical, a fund under Southern Fund holds a position. The Southern CSI 500 ETF (510500) reduced its holdings by 144,500 shares in the third quarter, now holding 8.042 million shares, which accounts for 0.76% of the circulating shares. The estimated floating loss today is approximately 7.3182 million CNY [2] - The Southern CSI 500 ETF (510500) was established on February 6, 2013, with a latest scale of 140.098 billion CNY. Year-to-date returns are 32.6%, ranking 1754 out of 4216 in its category; the one-year return is 30.54%, ranking 1659 out of 3885; and since inception, the return is 151.6% [2] - The fund manager of Southern CSI 500 ETF (510500) is Luo Wenjie, who has a cumulative tenure of 12 years and 195 days, with total fund assets of 170.445 billion CNY. The best fund return during his tenure is 151.8%, while the worst is -47.6% [2]